{"brief_title": "A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors", "brief_summary": "The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Lopinavir/ritonavir", "Ritonavir"], "criteria": "Inclusion: - HIV positive - Are at least 18 years old - Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening - HIV RNA level > 1000 copies/mL - Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor Exclusion: - Subject is pregnant or breast-feeding - Subject has received an investigational drug within 30 days prior to screening - Have a history of pancreatitis - History of intolerance to ritonavir - Abnormal laboratory tests at screening", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "HIV", "mesh_term": ["HIV Infections", "Ritonavir", "Lopinavir", "HIV Protease Inhibitors", "Protease Inhibitors", "Reverse Transcriptase Inhibitors"], "id": "NCT00038636"}